17P Efficacy and safety of furmonertinib as salvage treatment for EGFR-mutated NSCLC patients progressed on third-generation EGFR TKIs

The current standard treatment for EGFR mutated NSCLC patients progressed on third-generation EGFR TKI was chemotherapy. For patients retaining EGFR mutations after resistance, switching to more potent TKI provided another strategy. Furmonertinib was designed with unique chemical structure to improve potency and specificity targeting various EGFR mutations, and has been verified its superior efficacy and favorable safety profile in clinical trials. This study described the real-world efficacy and safety of furmonertinib as salvage treatment for EGFR-mutated NSCLC patients progressed on other third-generation EGFR TKIs. We retrospectively examined advanced NSCLC patients with EGFR mutations progressed on osimertinib and/or aumolertinib who were treated with furmonertinib with or without other treatment from Apr 12, 2021, to Dec 20, 2023. Objective response rate (ORR), disease control rate (DCR), progression-free survival (PFS) and safety were assessed. We included 43 patients, of which 37.2% progressed on first-line 3rd generation EGFR TKI, 23.2% patients failed to both osimertinib and aumolertinib, and 37.2% patients progressed in intracranial lesion. The median follow-up time was 6.1 months (range 0.9 - 27.1). The ORR and DCR were 18.6% and 79.1% respectively, the median PFS was 6.1 months (95% CI 4.2 - 8.0). In those patients received furmonertinib after failure of first-line 3rd generation EGFR TKI, the ORR and DCR were 25% and 87.5% respectively, the median PFS was 10.5 months (95% CI 0.0 - 23.6). In addition, treatment-emergent adverse events (TEAEs) of any grade occurred in 4.7% of patients (2/43), with no grade ≥3 TEAE was observed. Furmonertinib showed encouraging anti-tumor activity and an acceptable safety profile as salvage treatment for patient with EGFR mutated NSCLC progressed on 3rd generation EGFR TKI, especially in those with first-line 3rd generation EGFR TKI.